Department of Biochemistry, University of Alberta, Edmonton, AB T6G 2S2, Canada.
Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry, Moscow, 117997, Russia.
Antiviral Res. 2018 Jan;149:164-173. doi: 10.1016/j.antiviral.2017.11.018. Epub 2017 Nov 27.
Most antivirals target viral proteins and are specific for only one virus, or viral type. Whereas viral proteins are encoded in the plastic viral genome, virion lipids are not and their rearrangements during fusion are conserved among otherwise unrelated enveloped viruses. Antivirals that inhibit these lipid rearrangements could thus pose a high barrier to resistance and have broad-spectrum activity. Fusion occurs through a hemifusion stalk in which only the outer leaflets are fused and thus curved with a smaller radius for the polar heads than for the hydrophobic tails (negative curvature). Outer leaflets enriched in phospholipids with head groups of larger cross sections than their lipid tails ("inverted cone") disfavor negative curvature, inhibiting fusion. The rigid amphipathic fusion inhibitors (RAFIs) are synthetic compounds of inverted cone molecular geometry. They inhibit infectivity of otherwise unrelated enveloped viruses. The leading RAFI, aUY11, has an ethynyl-perylene hydrophobic and an uracil-arabinose polar moiety. aUY11 intercalates in viral envelopes and inhibits virion-to-cell fusion of a broad spectrum of otherwise unrelated enveloped viruses. Previous studies showed that amphipathicity, rigidity, and inverted cone molecular geometry were required. We propose that the inverted cone molecular geometry of the RAFIs increases the energy barrier for the hemifusion stalk, inhibiting fusion. Then, chemically distinct compounds with similar amphipathicity, rigidity, and inverted cone shape would have similar antiviral potencies, regardless of specific chemical groups. Alternatively, the perylene group exposed to visible light may induce viral lipid peroxidation. Then, the perylene group and absorbance at visible spectrum would be required. We now evaluated twenty-five chemically distinct RAFIs. The perylene moiety and absorption at visible spectrum were not required, but a minimum length of the hydrophobic moiety was, 10.3 Å. The arabino moiety could be modified or replaced by other groups. Cytidine was not tolerated. Bilayer intercalation was required but not sufficient. The vast majority of RAFIs had no overt cytotoxicity (CC > 20 μM; TI > 250-1200). Carbonyl or butylamide substitutions for arabino, or cytidine replacement for uracil, increased cytotoxicity. Cytotoxicity was mainly determined by the polar moiety and there was no correlation between antiviral and cytostatic activities. The definition of the effects of shape and chemical groups of the RAFIs opens the possibility to the rational design of lipid-acting antivirals active against a broad spectrum of enveloped viruses.
大多数抗病毒药物针对病毒蛋白,并且对一种病毒或病毒类型具有特异性。然而,病毒蛋白是在可塑性病毒基因组中编码的,而病毒粒子脂质不是,并且在融合过程中的重排在其他不相关的包膜病毒中是保守的。因此,抑制这些脂质重排的抗病毒药物可能对耐药性构成很高的障碍,并具有广谱活性。融合通过半融合柄发生,其中只有外小叶融合,因此极性头部的曲率比疏水性尾部(负曲率)小。富含头部横截面大于其脂质尾部的磷脂的外小叶(“倒锥形”)不利于负曲率,从而抑制融合。刚性两亲性融合抑制剂(RAFI)是倒锥形分子几何形状的合成化合物。它们抑制不相关包膜病毒的感染性。领先的 RAFI,aUY11,具有乙炔基-苝的疏水性和尿嘧啶-阿拉伯糖的亲水性部分。aUY11 嵌入病毒包膜中,并抑制广泛的不相关包膜病毒的病毒粒子与细胞融合。先前的研究表明,两亲性、刚性和倒锥形分子几何形状是必需的。我们提出 RAFI 的倒锥形分子几何形状增加了半融合柄的能量障碍,从而抑制融合。然后,具有相似两亲性、刚性和倒锥形形状的化学性质不同的化合物将具有相似的抗病毒效力,而与特定的化学基团无关。或者,暴露于可见光的苝基团可能会诱导病毒脂质过氧化。然后,需要苝基团和可见光谱的吸光度。现在我们评估了 25 种具有不同化学性质的 RAFI。苝基团和可见光谱的吸光度不是必需的,但疏水性部分的最小长度为 10.3 Å。阿拉伯糖基可以被修饰或被其他基团取代。胞嘧啶不能耐受。双层插入是必需的,但不是充分的。绝大多数 RAFI 没有明显的细胞毒性(CC>20 μM;TI>250-1200)。阿拉伯糖的羰基或丁酰胺取代物,或尿嘧啶的胞嘧啶取代物,增加了细胞毒性。细胞毒性主要由极性部分决定,抗病毒和细胞毒性活性之间没有相关性。RAFI 的形状和化学基团的影响的定义为针对广泛包膜病毒的脂质作用抗病毒药物的合理设计开辟了可能性。